logo
welcome
Investor's Business Daily

Investor's Business Daily

Moderna cuts full-year sales outlook, shares tumble 12% in premarket trade

Investor's Business Daily
Summary
Nutrition label

78% Informative

For the year , Moderna now expects $3 billion to $3.5 billion in sales, below its previous guidance for about $4 billion .

Moderna stock tumbled 12% in premarket trade.

The guidance comes as Moderna launches its second -ever product, a vaccine for respiratory syncytial virus.

VR Score

81

Informative language

84

Neutral language

46

Article tone

formal

Language

English

Language complexity

44

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links